Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JSKN016 + carboplatin + ivonescimab
- Development stage
- Phase 1
- Lead developer
- AlphaMab Oncology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
JSKN016 + carboplatin + ivonescimab is a triple combination therapy currently being investigated in clinical trials primarily for advanced malignant solid tumors, HER2-negative breast cancer, and non-small cell lung cancer. JSKN016 is a bispecific antibody-drug conjugate (ADC) targeting HER3 and TROP2, which delivers a cytotoxic topoisomerase I inhibitor (TOPIi) upon binding, causing tumor cell apoptosis and exhibiting a bystander effect on antigen-negative cells[1][2][4]. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to cell death. Ivonescimab is a bispecific monoclonal antibody targeting PD-1 and VEGF, functioning as a checkpoint inhibitor with anti-angiogenic properties. This combination is designed to simultaneously target tumor cell receptors, induce DNA damage, and suppress immune checkpoint and angiogenesis pathways for enhanced antitumor effect.
- Other names
- JSKN016JSKN-016JSKN 016carboplatinivonescimab
02
Targets
DNAERBB3 (Erb-b2 receptor tyrosine kinase 3)PDCD1 (Programmed cell death protein 1 receptor)TACSTD2 (Tumor-associated calcium signal transducer 2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on JSKN016 + carboplatin + ivonescimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JSKN016 + carboplatin + ivonescimab.